AtriCure Financial Statements (ATRC)
|
|
|
|
Report date
|
|
|
31.12.2022 |
22.02.2023 |
16.02.2024 |
14.02.2025 |
19.02.2026 |
|
05.05.2026 |
|
Currency
|
|
|
USD |
USD |
USD |
USD |
USD |
|
USD |
|
Financial report URL
|
|
|
|
|
|
|
|
|
|
|
|
Revenue, bln rub |
? |
|
330.4 |
330.4 |
399.2 |
465.3 |
534.5 |
|
552.2 |
|
Operating Income, bln rub |
|
|
-42.7 |
-42.7 |
-26.7 |
-40.0 |
-3.45 |
|
-1.97 |
|
EBITDA, bln rub |
? |
|
-46.2 |
-29.5 |
-8.11 |
-18.5 |
16.2 |
|
18.2 |
|
Net profit, bln rub |
? |
|
-46.5 |
-46.5 |
-30.4 |
-44.7 |
-11.4 |
|
-4.59 |
|
|
OCF, bln rub |
? |
|
|
-22.1 |
4.48 |
12.2 |
57.3 |
|
68.4 |
|
CAPEX, bln rub |
? |
|
|
16.9 |
42.0 |
23.5 |
9.05 |
|
13.7 |
|
FCF, bln rub |
? |
|
|
-39.0 |
-37.5 |
-11.3 |
48.3 |
|
61.5 |
|
Dividend payout, bln rub
|
|
|
|
0.000 |
0.000 |
0.000 |
0.000 |
|
0.000 |
|
|
Ordinary share dividend yield, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0.00% |
|
Dividend payout ratio, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0 |
|
|
OPEX, bln rub |
|
|
288.6 |
288.6 |
327.1 |
387.5 |
401.2 |
|
418.7 |
|
Cost of production, bln rub |
|
|
84.4 |
84.4 |
98.9 |
117.8 |
136.8 |
|
135.5 |
|
R&D, bln rub |
|
|
57.3 |
57.3 |
73.9 |
96.2 |
90.2 |
|
99.2 |
|
Interest expenses, bln rub |
|
|
0.000 |
4.99 |
6.93 |
6.41 |
5.88 |
|
5.90 |
|
|
Assets, bln rub |
|
|
585.4 |
585.4 |
613.9 |
609.3 |
654.2 |
|
644.0 |
|
Net Assets, bln rub |
? |
|
456.8 |
456.8 |
466.2 |
461.0 |
491.9 |
|
491.7 |
|
Debt, bln rub |
|
|
69.1 |
74.5 |
74.5 |
76.5 |
88.0 |
|
71.8 |
|
Cash, bln rub |
|
|
121.1 |
121.1 |
137.3 |
122.7 |
167.4 |
|
146.2 |
|
Net debt, bln rub |
|
|
-52.0 |
-46.6 |
-62.8 |
-46.2 |
-79.4 |
|
-74.4 |
|
|
Ordinary share price, rub |
|
|
44.4 |
44.4 |
35.7 |
30.6 |
39.6 |
|
33.5 |
|
Number of ordinary shares, mln |
|
|
42.1 |
45.7 |
46.3 |
47.0 |
47.8 |
|
48.3 |
|
|
Market cap, bln rub |
|
|
1 870 |
2 030 |
1 653 |
1 435 |
1 889 |
|
1 619 |
|
EV, bln rub |
? |
|
1 817 |
1 983 |
1 590 |
1 389 |
1 810 |
|
1 545 |
|
Book value, bln rub |
|
|
457 |
183 |
167 |
170 |
209 |
|
211 |
|
|
EPS, rub |
? |
|
-1.10 |
-1.02 |
-0.66 |
-0.95 |
-0.24 |
|
-0.10 |
|
FCF/share, rub |
|
|
0.00 |
-0.85 |
-0.81 |
-0.24 |
1.01 |
|
1.27 |
|
BV/share, rub |
|
|
10.8 |
3.99 |
3.61 |
3.61 |
4.38 |
|
4.37 |
|
|
EBITDA margin, % |
? |
|
-14.0% |
-8.93% |
-2.03% |
-3.98% |
3.04% |
|
3.30% |
|
Net margin, % |
? |
|
-14.1% |
-14.1% |
-7.62% |
-9.61% |
-2.14% |
|
-0.83% |
|
FCF yield, % |
? |
|
0.00% |
-1.92% |
-2.27% |
-0.78% |
2.56% |
|
3.80% |
|
ROE, % |
? |
|
-10.2% |
-10.2% |
-6.53% |
-9.70% |
-2.33% |
|
-0.93% |
|
ROA, % |
? |
|
-7.94% |
-7.94% |
-4.96% |
-7.34% |
-1.75% |
|
-0.71% |
|
|
P/E |
? |
|
-40.2 |
-43.7 |
-54.3 |
-32.1 |
-165.0 |
|
-352.5 |
|
P/FCF |
|
|
|
-52.0 |
-44.1 |
-127.5 |
39.1 |
|
26.3 |
|
P/S |
? |
|
5.66 |
6.14 |
4.14 |
3.08 |
3.53 |
|
2.93 |
|
P/BV |
? |
|
4.09 |
11.1 |
9.87 |
8.46 |
9.03 |
|
7.66 |
|
EV/EBITDA |
? |
|
-39.3 |
-67.2 |
-196.1 |
-74.9 |
111.4 |
|
84.8 |
|
Debt/EBITDA |
|
|
1.13 |
1.58 |
7.74 |
2.49 |
-4.89 |
|
-4.08 |
|
|
R&D/CAPEX, % |
|
|
|
339.7% |
176.0% |
410.0% |
996.3% |
|
725.6% |
|
|
CAPEX/Revenue, % |
|
|
0.00% |
5.11% |
10.5% |
5.04% |
1.69% |
|
2.47% |
|
| AtriCure shareholders |
